BioNTech Founders Forge New Path: A Return to Early Discovery

BioNTech's co-founders, Ugur Sahin and Oezlem Tuereci, plan to leave by year's end to start a new venture, causing BioNTech's shares to plummet. The couple aims to focus on mRNA-based drugs at an early stage, leaving questions about BioNTech's future direction and impact on shareholders.

In a surprising turn of events, BioNTech's co-founders Ugur Sahin and Oezlem Tuereci have announced their departure from the COVID-19 vaccine maker to embark on a new venture. This decision has sent shockwaves through the market, with BioNTech's shares dropping by over 20%, reaching their lowest point since August 2024.

As the masterminds behind the widely-used COVID-19 vaccine developed in collaboration with Pfizer, Sahin and Tuereci are prepared to become 'pioneers again.' Their departure signals a shift towards early-stage drug discovery, specifically focusing on mRNA technology, a field in which they've already achieved notoriety.

While the duo's new company is still in its nascent stages, discussions about potential funding and stake contributions from BioNTech are underway. Despite the uncertainty this move brings, BioNTech insists its cancer therapies and COVID-19 franchise will remain unaffected, striving to demonstrate their prolonged success post-pandemic.